PT-141: Complete Research Guide & Chemical Profile

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide that serves as a melanocortin receptor agonist. This research compound was originally developed as a derivative of Melanotan II and has gained significant attention in scientific circles for its unique properties and potential research applications.

The peptide features a molecular weight of 1,025.2 g/mol and follows the amino acid sequence Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH. Research-grade PT-141 is typically produced with a purity standard of ≥99.0%, ensuring consistent results in laboratory investigations.

Unlike its predecessor Melanotan II, PT-141 demonstrates selective activity at specific melanocortin receptors, making it a valuable tool for researchers studying receptor-mediated pathways and their associated biological processes.

PT-141's development stems from extensive research into melanocortin receptor systems and their role in various physiological processes. Initial studies focused on understanding how this peptide interacts with melanocortin receptors, particularly MC3R and MC4R subtypes.

Research has demonstrated that PT-141 exhibits distinct pharmacological properties compared to other melanocortin agonists. Laboratory studies indicate that the compound shows selective receptor binding patterns, which has made it a subject of interest for researchers investigating receptor specificity and signaling pathways.

Published research has explored PT-141's effects in various experimental models, with studies examining its influence on neurotransmitter systems and central nervous system pathways. These investigations have contributed valuable insights into melanocortin receptor function and associated biological mechanisms.

Clinical research programs have investigated PT-141's safety profile and pharmacokinetic properties, providing researchers with essential data for designing laboratory protocols and understanding the compound's behavior in biological systems.

PT-141 functions as a selective melanocortin receptor agonist, primarily targeting MC3R and MC4R subtypes located in the central nervous system. Research suggests that the peptide's mechanism involves binding to these G-protein coupled receptors and activating downstream signaling cascades.

Upon receptor binding, PT-141 appears to stimulate adenylyl cyclase activity, leading to increased cyclic adenosine monophosphate (cAMP) levels within target cells. This elevation in cAMP subsequently activates protein kinase A (PKA), which phosphorylates various downstream effector proteins.

Laboratory studies indicate that PT-141's activity may influence neurotransmitter release patterns, particularly affecting dopaminergic and noradrenergic pathways in specific brain regions. This neuromodulatory activity distinguishes PT-141 from other melanocortin receptor agonists and contributes to its unique research profile.

The peptide's selectivity for certain melanocortin receptor subtypes appears to be influenced by its structural modifications, including the N-terminal acetylation and specific amino acid substitutions that differentiate it from naturally occurring melanocortin peptides.

PT-141 exhibits specific chemical characteristics that researchers must consider when designing experimental protocols. The peptide demonstrates stability under appropriate storage conditions, typically requiring storage at -20°C or below to maintain its structural integrity over extended periods.

Research-grade PT-141 is supplied as a lyophilized powder with a purity standard of ≥99.0% as determined by HPLC analysis. The compound shows good solubility in sterile water and various buffer systems commonly used in laboratory settings, though researchers should prepare fresh solutions when possible to ensure optimal activity.

The peptide's molecular structure includes several modifications that enhance its stability compared to natural melanocortin peptides. The N-terminal acetylation and incorporation of norleucine (Nle) contribute to increased resistance to enzymatic degradation, making it suitable for extended research applications.

Laboratory analysis typically confirms PT-141's identity through mass spectrometry and amino acid composition analysis. Researchers should verify these parameters when establishing new research protocols to ensure consistent experimental conditions.

Researchers seeking high-quality PT-141 for laboratory investigations can find verified vendors and third-party tested batches on ChemVerify. The platform maintains a comprehensive database of suppliers who meet stringent quality standards for research peptides.

ChemVerify's verification process includes assessment of analytical certificates, third-party testing results, and supplier compliance with research-grade standards. This ensures that researchers have access to PT-141 samples that meet the ≥99.0% purity requirements essential for reliable experimental outcomes.

The platform's detailed product listings at /product/pt-141 provide researchers with comprehensive information about available PT-141 sources, including batch-specific analytical data, storage recommendations, and supplier verification status.

**What distinguishes PT-141 from other melanocortin receptor agonists?**

PT-141 demonstrates selective activity at MC3R and MC4R subtypes, unlike broad-spectrum melanocortin agonists. Its structural modifications, including N-terminal acetylation and norleucine incorporation, contribute to enhanced stability and specific receptor binding patterns that make it valuable for targeted research applications.

**How should PT-141 be stored for laboratory research?**

Research-grade PT-141 should be stored as a lyophilized powder at -20°C or below, protected from light and moisture. Once reconstituted, solutions should be prepared fresh when possible or stored at 4°C for short-term use. Avoid repeated freeze-thaw cycles to maintain peptide integrity.

**What analytical methods are used to verify PT-141 quality?**

PT-141 quality is typically verified through HPLC analysis for purity determination, mass spectrometry for molecular weight confirmation, and amino acid analysis for sequence verification. Research-grade material should meet ≥99.0% purity standards with appropriate analytical certificates.

**What are the key considerations for PT-141 research protocols?**

Researchers should consider PT-141's receptor selectivity, stability requirements, and solubility characteristics when designing experimental protocols. The peptide's activity at specific melanocortin receptor subtypes may require specialized assay conditions and appropriate control compounds for comparative studies.

**How does PT-141's mechanism differ from Melanotan II?**

While both peptides target melanocortin receptors, PT-141 shows greater selectivity for MC3R and MC4R subtypes with reduced activity at MC1R compared to Melanotan II. This selectivity profile makes PT-141 particularly valuable for research focusing on specific receptor-mediated pathways without broader melanocortin system activation.

**What should researchers know about PT-141's pharmacokinetic properties?**

Research indicates that PT-141 demonstrates distinct pharmacokinetic characteristics, though specific half-life data remains limited in published literature. Laboratory studies suggest the peptide maintains biological activity over extended periods, making it suitable for research protocols requiring sustained receptor engagement.

• Read more: Hexarelin: Complete Research Guide & Chemical Profile → https://www.chemverify.com/learn/hexarelin-research-guide-chemical-profile
• Read more: How Fast Do Peptides Work? Expected Timelines for BPC-157, Semaglutide, Ipamorelin & More → https://www.chemverify.com/learn/how-fast-do-peptides-work-timelines
• Read more: Retatrutide: Complete Research Guide & Chemical Profile → https://www.chemverify.com/learn/retatrutide-research-guide-chemical-profile
• Read more: Tirzepatide: Complete Research Guide & Chemical Profile → https://www.chemverify.com/learn/tirzepatide